

Patented next generation radiation dose monitoring for cancer patients and interventional and diagnostic procedures.

TRANSACTION SUMMARY

Issuer	Electrogenics Laboratories Ltd (ELL) or the Company
Offer	Series-A raise \$1.5m by issuing up to 16,666,667 shares (~13.5% of the Company) at A\$0.09 per share. Directors reserve the right to take overs. IPO planned in ~18 months with a target price of .30 to .50c a share subject to markets/milestones.

Lead Broker Novus Capital Limited

COMPANY OVERVIEW

ELL is an unlisted Australian public company formed in conjunction with University of Wollongong (UOW).

ELL holds the worldwide exclusive rights to commercialise the MOSkin™ Technology.

Overall winner and winner Medtech & Pharma, Australian Technologies Competition 2020



COMPANY HIGHLIGHTS


- ELL's breakthrough dosimetry sensor technology is a precise, easy to use, cost effective new method to independently measure radiation doses **received** by patients during medical radiation procedures. Its use can help reduce and, in some cases, eliminate the risks of unwanted organ or tissue damage from unintended or accidental radiation overdosing or under dosing
- MOSkin™ Technology
 - ✓ Targets global markets, including radiotherapy for cancer treatment and interventional radiology such as angiograms, liver, lung, vascular and spinal surgeries
 - ✓ Successfully tested on over 2,000 patients and simulations in over 20 international hospitals and clinics
 - ✓ Fully patented in major markets (USA, EU, UK, China)
- Leading Australian industrial design, electronics, QA and regulatory consultants engaged & developing products
- Proven leadership team with broad experience
- Conservative valuation

MOSkin™ POTENTIAL GLOBAL MARKETS

Worldwide, radiation therapy for cancer is delivered to around 6m patients a year (just under a 33% of all cases) With an ave. of 20 fractions per case = 120m procedures/yr) Add to that approx. 40m interventional radiology procedures/yr. totals ~160m procedures times 3 dosimeters per procedure represents ~500 m/yr potential total global market. Expected W/sale selling price of \$15 - \$18 with unit cost prices \$10 down to \$7 with volume. ELL's conservative forecasts next page show market penetration of less than 5%. by year 4. However, thereafter much greater penetration, is expected.

Currently

- Radiotherapy cancer clinics rely on Treatment Planning System **estimates** of the actual dose received by patients.
- Existing dosimeters in clinical use are complex, expensive, time consuming, can't accurately measure skin dose and in most cases do not provide immediate or real time critical data.
- Interventional radiologists have very limited independent QA tools to monitor actual cumulative doses received by patients during surgical procedures risking unintended severe radiation damage to patient skin tissue.
- Increasing international adoption of higher intensity 'flash therapy' for the treatment of cancer further increases the risks unwanted tissue and organ damage.



MOSkin™ PRODUCT



MOSkin™ Technology developed by the Centre for Medical Radiation Physics at UOW under the leadership of Distinguished Prof. Anatoly Rozenfeld MSc PhD.

The only dosimeter technology in the world able to precisely measure radiation skin dose at recommended WED reference standard set by International Commission on Radiation Measurements and Units (ICRU). The highest radiation dose is at the entrance site of the radiation beam.

- MOSkin™ Sensors are inexpensive, single use disposable devices that are transparent under X-ray and have no effect on the radiation field. An industry first. When connected via wireless Bluetooth to the MOSkin™ Reader, the sensor provides real time data, recording the precise radiation dose received by patients during each procedure.
- Benefits to clinics and hospitals includes significant cost savings from reduced patient set up time, single use/disposable (no need to remove sanitise and store for reuse), immediate data retrieval, reduced risk of human or machine errors and independent verification (QA) giving increased confidence and certainty in procedure and patient outcomes.



ELECTROGENICS LABORATORIES LTD

Capital Raising of AUD\$1.5 million.

FOR SOPHISTICATED AND PROFESSIONAL S.708 INVESTORS ONLY



CAPITAL STRUCTURE

CAPITAL STRUCTURE AFTER SERIES-A - OFFER \$ 1.5M

University of Wollongong (UOW)	11,475,000	9.26%
Founders	63,075,000	50.90%
CEO, director management pool	6,000,000	4.84%
Service Providers	9,517,500	7.68%
Shareholders Seed Round Offer	17,178,825	13.86%
New Investors Series-A Offer	16,666,667	13.45%
TOTAL	123,912,992	100.00%
IMPLIED MARKET CAP	\$11,152,169	
ENTERPRISE VALUE	\$9,652,169	

Minimum raise \$1,500,000. Series-B raise for \$2,500,000 expected in March 2022. Note: if Series A is oversubscribed Series B may not be needed.

IPO planned for Q2/3 2023 Target 30c to 50c a share, subject to market conditions, regulatory approvals, and a variety of relevant factors.

APPLICATION OF FUNDS

Prepare and submit regulatory applications for the TGA, FDA and EU

Optimise Engineering and design for volume manufacture and cost

To start setting up supply chain and a sales, distribution and support network in major markets.

Use of Funds (A\$)	\$1,500,000
R&D Engineering – electronics and industrial design for volume manufacture	\$620,000
US, Australian and EU regulatory approvals	\$180,000
Technical & Device Support Expenses	\$50,000
Marketing & Business Development team set up	\$30,000
Exec. and non-exec directors Fees (capped)	\$180,000
Legal, Accounting, Consultants & Audit	\$40,000
Engagement of UOW	\$30,000
Other Corporate Overheads	\$40,000
Fund Raising Costs	\$100,000
IPO Preparation Costs	\$80,000
Working Capital (incl. inventory costs)	\$150,000
Total (rounded to nearest 10,000)	\$1,500,000

FINANCIAL FORECASTS

Summary P&L '000's	Year 0 CY22	Year 1 CY23	Year 2 CY24	Year 3 CY25	Year 4 CY26
Revenue (\$ million)	\$0	\$3,390	\$18,260	\$43,870	\$81,700
UOW License	\$0	\$140	\$730	\$1,760	\$3,270
Cost of Goods Sold	\$0	\$1,660	\$8,130	\$19,560	\$32,010
Gross Profit ('000's)	\$0	\$1,590	\$9,420	\$22,550	\$46,420
GM margin	0%	47%	52%	51%	57%
Sale & Mktg Expenses	\$330	\$1,260	\$3,090	\$6,710	\$13,620
R&D Expenses (Net)	\$1,850	\$520	\$910	\$2,190	\$4,080
Support Expenses	\$210	\$760	\$1,020	\$1,680	\$5,240
Corporate Overheads	\$760	\$1,300	\$2,160	\$3,140	\$4,580
Pre IPO & IPO Costs	\$510	\$150	\$0	\$0	\$0
Total Expenses	\$3,660	\$3,990	\$7,180	\$13,720	\$27,520
EBIT (\$million)	-\$3.360	-\$2,400	\$2.240	\$8,830	\$18,900
EBIT %	0%	-71%	12%	20%	23%

R&D expenses net of rebates

Conservative Yr. 4 sales represent less than 5% of total market potential

DIRECTORS & ADVISORY BOARD

Kim Lyle Chairman and CEO

Kim has served as Chairman, CEO or Executive Director on the boards of six Australian public companies.

Srikanth Markonda Director Operations

Sri holds a Master of Technology, certified in Artificial Intelligence from MIT and Project Management from PMI. Served as Global CTO & COO of Emagine Int.

David Walker Director Legal and Company Secretary

David is a senior corporate lawyer with 30 years commercial practice experience and has been a director of two public companies.

Professor Michael Jackson – Medical Advisor

Director Radiation Oncology at Prince of Wales Hospital, served on Board Faculty of Radiation Oncology Royal Australian and N.Z. College of Radiologists and as Chairman of Radiation Oncology Group, Clinical Oncological Society of Australia.

James Stanistreet - Med tech Marketing Advisor

Senior Advisor Bio Connex US and Cortical Dynamics Ltd Perth. Served Medtronic Managing Director of Australia & N.Z. and as Vice Chairman of the Medical Technology Association of Australia.

Distinguished Professor Anatoly Rozenfeld University of Wollongong

Professor Rozenfeld inventor and Founder CMRP at UOW. Chair of International Solid State Dosimetry Organization (ISSDO), Founder/General Chair of Mini-Micro and Nano-Dosimetry (MMND) and General Chair of IEEE NSS MIC 2018.

MORE INFORMATION



Gavan Farley, Director Corporate
Novus Capital Ltd.
Ph. +61 2 9375 0114 Mobile +61 420 520 300
gavan.farley@novuscapital.com.au

DISCLAIMER & DISCLOSURE: Novus Capital Limited (ACN: 006 711 995) is a holder of an Australian Financial Services Licence (AFSL No. 238168). Novus Capital and its associates make no recommendations as to whether you should participate in the issue by the Company nor do they make any recommendation or warranty to you concerning the shares or accuracy, reliability or completeness of the information provided or the performance of the Company. This note is intended to provide background information only and does not purport to make any recommendation upon which you may reasonably rely without taking further and more specific advice. You should make your own decision whether to participate based on your own enquiries. The information provided does not purport to cover all relevant information about any potential investment in the Company. Professional & Sophisticated Investors: This document is intended for sophisticated and/or professional investors only as defined in s.708 of the Corporations Act. DISCLOSURE: Important: Novus Capital Ltd in its role to assist in the Capital Raising and pursuant to its Mandate with the Company will be paid fees in the Offer and Capital Raising. Novus Capital as principal, its directors and staff may participate in this issue.